169 related articles for article (PubMed ID: 9661900)
1. Antibodies against GD2 ganglioside can eradicate syngeneic cancer micrometastases.
Zhang H; Zhang S; Cheung NK; Ragupathi G; Livingston PO
Cancer Res; 1998 Jul; 58(13):2844-9. PubMed ID: 9661900
[TBL] [Abstract][Full Text] [Related]
2. Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21.
Ragupathi G; Livingston PO; Hood C; Gathuru J; Krown SE; Chapman PB; Wolchok JD; Williams LJ; Oldfield RC; Hwu WJ
Clin Cancer Res; 2003 Nov; 9(14):5214-20. PubMed ID: 14614001
[TBL] [Abstract][Full Text] [Related]
3. Impact of minimal tumor burden on antibody response to vaccination.
Kim SK; Wu X; Ragupathi G; Gathuru J; Koide F; Cheung NK; Panageas K; Livingston PO
Cancer Immunol Immunother; 2011 May; 60(5):621-7. PubMed ID: 21267719
[TBL] [Abstract][Full Text] [Related]
4. Ganglioside vaccines with emphasis on GM2.
Livingston P
Semin Oncol; 1998 Dec; 25(6):636-45. PubMed ID: 9865678
[TBL] [Abstract][Full Text] [Related]
5. Expansion of natural killer cells in mice transgenic for IgM antibody to ganglioside GD2: demonstration of prolonged survival after challenge with syngeneic tumor cells.
Kawashima I; Yoshida Y; Taya C; Shitara H; Yonekawa H; Karasuyama H; Tada N; Furukawa K; Tai T
Int J Oncol; 2003 Aug; 23(2):381-8. PubMed ID: 12851687
[TBL] [Abstract][Full Text] [Related]
6. Disialoganglioside GD2 anti-idiotypic monoclonal antibodies.
Cheung NK; Canete A; Cheung IY; Ye JN; Liu C
Int J Cancer; 1993 May; 54(3):499-505. PubMed ID: 8509225
[TBL] [Abstract][Full Text] [Related]
7. DNA vaccine expressing the mimotope of GD2 ganglioside induces protective GD2 cross-reactive antibody responses.
Bolesta E; Kowalczyk A; Wierzbicki A; Rotkiewicz P; Bambach B; Tsao CY; Horwacik I; Kolinski A; Rokita H; Brecher M; Wang X; Ferrone S; Kozbor D
Cancer Res; 2005 Apr; 65(8):3410-8. PubMed ID: 15833876
[TBL] [Abstract][Full Text] [Related]
8. Immunization of melanoma patients with BEC2-keyhole limpet hemocyanin plus BCG intradermally followed by intravenous booster immunizations with BEC2 to induce anti-GD3 ganglioside antibodies.
Yao TJ; Meyers M; Livingston PO; Houghton AN; Chapman PB
Clin Cancer Res; 1999 Jan; 5(1):77-81. PubMed ID: 9918205
[TBL] [Abstract][Full Text] [Related]
9. Induction of IgG antibodies against the GD2 carbohydrate tumor antigen by vaccination with peptide mimotopes.
Riemer AB; Förster-Waldl E; Brämswig KH; Pollak A; Zielinski CC; Pehamberger H; Lode HN; Scheiner O; Jensen-Jarolim E
Eur J Immunol; 2006 May; 36(5):1267-74. PubMed ID: 16568495
[TBL] [Abstract][Full Text] [Related]
10. Peptides mimicking GD2 ganglioside elicit cellular, humoral and tumor-protective immune responses in mice.
Wondimu A; Zhang T; Kieber-Emmons T; Gimotty P; Sproesser K; Somasundaram R; Ferrone S; Tsao CY; Herlyn D
Cancer Immunol Immunother; 2008 Jul; 57(7):1079-89. PubMed ID: 18157673
[TBL] [Abstract][Full Text] [Related]
11. Induction of antibodies against GD3 ganglioside in melanoma patients by vaccination with GD3-lactone-KLH conjugate plus immunological adjuvant QS-21.
Ragupathi G; Meyers M; Adluri S; Howard L; Musselli C; Livingston PO
Int J Cancer; 2000 Mar; 85(5):659-66. PubMed ID: 10699946
[TBL] [Abstract][Full Text] [Related]
12. Keyhole limpet hemocyanin conjugate vaccines against cancer: the Memorial Sloan Kettering experience.
Musselli C; Livingston PO; Ragupathi G
J Cancer Res Clin Oncol; 2001 Oct; 127 Suppl 2():R20-6. PubMed ID: 11768620
[TBL] [Abstract][Full Text] [Related]
13. Preclinical evaluation in nonhuman primates of murine monoclonal anti-idiotype antibody that mimics the disialoganglioside GD2.
Sen G; Chakraborty M; Foon KA; Reisfeld RA; Bhattacharya-Chatterjee M
Clin Cancer Res; 1997 Nov; 3(11):1969-76. PubMed ID: 9815586
[TBL] [Abstract][Full Text] [Related]
14. GD3 vaccines for melanoma: superior immunogenicity of keyhole limpet hemocyanin conjugate vaccines.
Helling F; Shang A; Calves M; Zhang S; Ren S; Yu RK; Oettgen HF; Livingston PO
Cancer Res; 1994 Jan; 54(1):197-203. PubMed ID: 8261439
[TBL] [Abstract][Full Text] [Related]
15. Approaches to augmenting the immunogenicity of melanoma gangliosides: from whole melanoma cells to ganglioside-KLH conjugate vaccines.
Livingston PO
Immunol Rev; 1995 Jun; 145():147-66. PubMed ID: 7590824
[TBL] [Abstract][Full Text] [Related]
16. GM2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21.
Helling F; Zhang S; Shang A; Adluri S; Calves M; Koganty R; Longenecker BM; Yao TJ; Oettgen HF; Livingston PO
Cancer Res; 1995 Jul; 55(13):2783-8. PubMed ID: 7796403
[TBL] [Abstract][Full Text] [Related]
17. A novel O-acetylated ganglioside detected by anti-GD2 monoclonal antibodies.
Ye JN; Cheung NK
Int J Cancer; 1992 Jan; 50(2):197-201. PubMed ID: 1730513
[TBL] [Abstract][Full Text] [Related]
18. Vaccination with a bivalent G(M2) and G(D2) ganglioside conjugate vaccine: a trial comparing doses of G(D2)-keyhole limpet hemocyanin.
Chapman PB; Morrisey D; Panageas KS; Williams L; Lewis JJ; Israel RJ; Hamilton WB; Livingston PO
Clin Cancer Res; 2000 Dec; 6(12):4658-62. PubMed ID: 11156217
[TBL] [Abstract][Full Text] [Related]
19. Synergistic effect of dendritic cell vaccination and anti-CD20 antibody treatment in the therapy of murine lymphoma.
Gadri Z; Kukulansky T; Bar-Or E; Haimovich J; Hollander N
J Immunother; 2009 May; 32(4):333-40. PubMed ID: 19342972
[TBL] [Abstract][Full Text] [Related]
20. Tumor targeting of the IL-15 superagonist RLI by an anti-GD2 antibody strongly enhances its antitumor potency.
Vincent M; Bessard A; Cochonneau D; Teppaz G; Solé V; Maillasson M; Birklé S; Garrigue-Antar L; Quéméner A; Jacques Y
Int J Cancer; 2013 Aug; 133(3):757-65. PubMed ID: 23354868
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]